Lipedema is a clinical diagnosis. There is no confirmatory blood test, no specific imaging finding, and no biopsy result that establishes it with certainty. Diagnosis rests on the clinical picture: bilateral symmetrical fat deposits on the lower limbs and sometimes the arms, sparing of the hands and feet, pain or tenderness on palpation, a history of easy bruising, and fat that does not respond to calorie restriction or exercise. The Stemmer sign is negative, which helps distinguish Lipedema from lymphoedema.

The condition is almost exclusively seen in women and has a strong familial pattern. It typically emerges or worsens at hormonal turning points: puberty, pregnancy, and menopause. Co-existing obesity is common and does not exclude the diagnosis. It is important to distinguish between the Lipedema tissue, which is painful, tender, and symmetrically distributed with a clear anatomical boundary at the ankles and wrists, and any co-existing generalised adiposity. A patient can have both. Advising weight loss as a treatment for the Lipedema component is not evidence-based and is likely to delay appropriate management.

The differential diagnosis most relevant in clinical practice is lymphoedema. The key distinguishing features are the bilateral symmetry and sparing of the extremities in Lipedema, the absence of pitting on pressure, and the negative Stemmer sign. Where both conditions are present, this is called lipolymphoedema and is more common in later-stage or long-untreated Lipedema. Chronic venous insufficiency, lipohypertrophy, and familial partial lipodystrophy should also be considered in the differential.

Management is staged by the severity of the condition and the patient’s symptoms and goals. Conservative management, including compression therapy, manual lymphatic drainage, and appropriate exercise, is appropriate at all stages and can provide meaningful symptom relief. Liposuction is the only intervention that addresses the underlying tissue and has a growing evidence base for symptom reduction and quality of life improvement, particularly at Stages 2 and 3. The 2021 US Standard of Care and the 2024 German S2k guideline both support surgical referral where conservative management is insufficient. In the UK, NICE NG203 (2022) sets out the framework for assessment and management within the NHS.

Many patients presenting with suspected Lipedema will have been told previously that their symptoms are due to obesity, poor diet, or inactivity. They may have received this message from multiple clinicians over many years. Confirming the diagnosis clearly, naming the condition, and explaining that it is not caused by lifestyle choices is itself a significant clinical intervention. Patients who have received a confident, accurate diagnosis consistently report that it changes their relationship to their own symptoms and their capacity to engage with management. A referral to a lymphoedema service with Lipedema experience, or to a specialist Lipedema clinic where available, is the appropriate next step in most cases.